Last reviewed · How we verify
Ruconest
At a glance
| Generic name | Ruconest |
|---|---|
| Also known as | SOC |
| Sponsor | Bernstein Clinical Research Center |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Hereditary C1 esterase inhibitor deficiency - deficient factor
Common side effects
- Headache
- Nausea
- Diarrhea
Serious adverse events
- Anaphylaxis
Key clinical trials
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (PHASE2)
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection (PHASE2)
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation (PHASE2)
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) (PHASE2)
- Berinert (C1INH) vs Placebo for DGF/IRI (PHASE1, PHASE2)
- Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) (PHASE4)
- Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ruconest CI brief — competitive landscape report
- Ruconest updates RSS · CI watch RSS
- Bernstein Clinical Research Center portfolio CI